Latest News - Bristol-Myers Squibb
Top Corporates Hub
Bristol-Myers Squibb
Bristol Myers: Dividend Growth, Raised Guidance, And A Double Beat
01.08.2025 17:00
Discover why Bristol-Myers Squibb (BMY) is a contrarian value play with a 5.39% dividend yield, strong growth strategy, and long-term potential.
Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields
01.08.2025 13:42
Bristol-Myers Squibb remains a compelling Buy despite the market's over-reaction to the industry and macro headwinds. Learn more about BMY stock here.
Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)
01.08.2025 13:14
Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after earnings. Read the latest stock analysis here.
Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?
01.08.2025 12:00
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Bristol-Myers Squibb (BMY) Sees Healthy Momentum in Growth Portfolio in Q2 2025
01.08.2025 03:32
Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 31, the company reported results for Q2 2025, wherein it saw healthy momentum throughout its Growth Portfolio and continued to optimize its cost structure. In the back half, Bristol-Myers Squibb Company (NYSE:BMY) remains focused on advancing transformational medicines […]
Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.
31.07.2025 12:14
Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs expire in the coming years.
Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations
31.07.2025 11:57
Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a charge related to its BioNTech partnership.
Bristol-Myers Squibb shares rise as Q2 results boosted by growth portfolio
31.07.2025 11:48
Investing.com -- Bristol-Myers Squibb reported second-quarter earnings that exceeded analyst expectations, driven by strong performance across its Growth Portfolio, prompting the pharmaceutical giant to raise its full-year guidance. The stock rose 2.2% following the announcement.
Bristol Myers: Q2 Earnings Snapshot
31.07.2025 11:18
PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported second-quarter profit of $1.31 billion. On a per-share basis, the Princeton, New Jersey-based company said it had net income of 64 cents. Earnings, adjusted for non-recurring costs and amortization costs, were $1.46 per share.
Bristol Myers posts better-than-expected second quarter results on strength of top sellers
31.07.2025 11:01
(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its most established and best-selling brands, blood thinner Eliquis and cancer treatments Opdivo and Revlimid. Shares of the drugmaker rose over 3% to $47.48 in premarket trading. Revenue in the quarter, which analysts had expected to fall due to the loss of patent protection on some of its products, including Revlimid, rose 1% to $12.3 billion.
Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
31.07.2025 10:59
PRINCETON, N.J., July 31, 2025--Bristol Myers Squibb Reports Second Quarter Financial Results for 2025
Bristol-Myers Squibb Company 2025 Q2 - Results - Earnings Call Presentation
31.07.2025 10:01
The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2025 Q2 earnings call.
Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA
31.07.2025 09:43
Discover key insights with the "Multiple Sclerosis - Global Clinical Trials Review, 2025" report. Gain an overview of global MS clinical trial landscapes, including data by region, phase, and sponsor. Identify top drugs and trial trends to optimize strategies. Enhance decision-making and competitive edge.Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Multiple Sclerosis - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial re
Merck Earnings Beat Analyst Estimates. Why the Stock Is Dropping.
29.07.2025 15:16
There is a growing list of challenges to drugs and programs Merck hopes will take up the slack from Keytruda.
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
29.07.2025 13:38
EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.
Bain leads $300M investment in startup built on Bristol Myers immune drugs
29.07.2025 08:43
Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five drugs that no longer fit its plans.
Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings
28.07.2025 16:59
Three emerging biotech companies — Elicio Therapeutics, Cellectis, and Autolus Therapeutics — are attracting “Strong Buy” analyst ratings in 2025 as major clinical, regulatory, and commercial catalysts position them for standout growth in the cancer treatment market.
Healthcare Earnings Are Coming. 4 Big Questions for CVS, Humana, Merck, UnitedHealth, and More.
28.07.2025 16:40
The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here are five problems they need to address.
Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team
28.07.2025 15:01
Vascarta Inc. today announced the addition of Janet Loesberg, PharmD, as the company's Fractional Chief Strategy Officer, effective immediately. Dr. Loesberg will be responsible for corporate strategy development, portfolio and pipeline management, strategic communications and fundraising/investor relations. She will report to Dr. Richard Prince, Chairman, CEO & President.
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
28.07.2025 14:28
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.